ACS Chemical Neuroscience
November 15, 2023
L Jacob Flameling, Jacob S. Aday, Michiel van Elk
ADVERTISEMENT RETURN TO ARTICLES ASAPPREVViewpointNEXTExpectancy Effects Cannot Be Neglected in MDMA-Assisted Therapy ResearchL. Jacob FlamelingL. Jacob FlamelingInstitute of Psychology, Leiden University, Leiden 2333 AK, The NetherlandsMore by L. Jacob Flamelinghttps://orcid.org/0000-0002-1425-1180, Jacob S. AdayJacob S. AdayDepartment of Anesthesiology, University of Michigan, Ann Arbor,...
Diseases
November 3, 2023
Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al.
16 citations
Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved pharmacotherapy and psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we review clinical trials and research on...
Nature Medicine
October 1, 2023
Jennifer Mitchell, Marcela Ot’alora G., Bessel Van der Kolk et al.
400 citations
This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-traumatic stress disorder (PTSD). Changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) and...
Mental Health Weekly
September 25, 2023
Valerie A. Canady
The third part of a new study assessing MDMA‐assisted therapy, a psychedelic drug also known as Ecstasy, has revealed improvement in diverse individuals suffering with severe post‐traumatic stress disorder (PTSD). The study, “MDMA‐assisted therapy for moderate to severe PTSD: a randomized, placebo‐controlled phase 3 trial,” published Sept. 14 in Nature Medicine.
Psychiatric News
September 22, 2023
Back to table of contents Previous article Next article Clinical & ResearchFull AccessMDMA-Assisted Therapy for PTSD Shows Promise for Patients of Diverse BackgroundsSearch for more papers by this authorPublished Online:22 Sep 2023https://doi.org/10.1176/appi.pn.2023.10.10.60AbstractMDMA appears to enhance the ability of individuals with PTSD to benefit from psychotherapy by softening their...
Current Problems of Psychiatry
September 22, 2023
Wiktoria Bojarska, Karolina Bury, Radosław Januszczak et al.
Introduction: Post-traumatic Stress Disorder (PTSD) is a mental illness caused by exposure to a traumatic event. The current treatment includes trauma-focused psychotherapy along with selective serotonin reuptake inhibitors (SSRI). It is estimated that for about 40-60% of patients it does not bring the desired improvement, which prompted scientists to look for new methods of pharmacotherapy....
Journal of Education, Health and Sport
August 15, 2023
Karol Womperski, Rafał Bogacz, Magdalena Gaik et al.
1 citation
Introduction: Post-traumatic stress disorder (PTSD) is a common health issue of complex etiology significantly deteriorating functioning in everyday life. It may develop as a result of exposure to traumatic events like traffic accidents, war experience, sexual abuse and domestic violence. Current methods of treatment consist of trauma-oriented psychotherapy supported by selective serotonin...
Nature
July 13, 2023
Rich Haridy
55 citations
Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed. Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed.
British medical journal
July 11, 2023
B. Nogrady
18 citations
The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...
Focus
July 1, 2023
Benjamin R. Lewis, Kevin Byrne
9 citations
Posttraumatic stress disorder (PTSD) is a common chronic and disabling psychiatric disorder that may develop after exposure to a traumatic life event. There are existing evidence-based psychotherapies and pharmacotherapies for PTSD; however, these treatments have significant limitations. 3,4-methylenedioxymethamphetamine (MDMA) was granted "breakthrough therapy" status by the U.S. Food and Drug...